We rank companies based on fund manager, research analyst and news sentiment
BVS stock icon

Bioventus
BVS

$4.48
1.54%
 

About: Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Employees: 970

0
Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

162% more call options, than puts

Call options by funds: $980K | Put options by funds: $375K

92% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 12

90% more capital invested

Capital invested by funds: $109M [Q3] → $207M (+$98M) [Q4]

63% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 16

16% more funds holding

Funds holding: 67 [Q3] → 78 (+11) [Q4]

9.81% more ownership

Funds ownership: 52.55% [Q3] → 62.36% (+9.81%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$7
56%
upside
Avg. target
$8
79%
upside
High target
$9
101%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Craig-Hallum
Alexander Nowak
101%upside
$9
Buy
Maintained
13 Mar 2024
Canaccord Genuity
William Plovanic
56%upside
$7
Buy
Upgraded
7 Dec 2023

Financial journalist opinion